Etravirine — an approved anti-viral therapy for HIV — is expected to soon enter clinical testing as…
Articles by Marta Figueiredo, PhD
Minoryx Therapeutics’ lead investigational therapy leriglitazone (MIN-102) has been granted orphan drug designation by the European Commission for treating…
Removal of the genetic defect that causes Friedreich’s ataxia (FA) in heart cells derived from a patient with heart…
Muscle stimulation through focal vibrations produced by a specialized device may prevent further deterioration of motor function in children with…
A treatment approach that uses genetically engineered proteins was able to significantly increase the levels of expression of the…
Friedreich’s ataxia patients produce less sweat than healthy people, which may be a useful biomarker of disease severity and…
Omaveloxolone, Reata Pharmaceuticals’ investigational candidate for the treatment of Friedreich’s ataxia (FA), has been granted orphan drug status…
The clinical benefits of stem cell therapy in Friedreich’s ataxia patients will be assessed in a small pilot study at…